Womens Health

Burjeel Holdings Convenes UNGA Roundtable on $1 Trillion Women's Health Gap

New York – September 25, 2026 -- Global healthcare, investment, philanthropy and government leaders convened at a roundtable on the sidelines of the 81st United Nations General Assembly to address a women's health gap that the World Economic Forum projects could exceed $1 trillion annually by 2040 if unaddressed. The session, titled "The $1 Trillion Case for Women's Health," was convened by Burjeel Holdings, a super-specialty healthcare provider operating across the UAE, Oman and Saudi Arabia.

Saudi Ambassador Reema Bandar Al-Saud calls for lifelong, integrated women's healthcare investment

HRH Ambassador Reema Bandar Al-Saud, Saudi Arabia's envoy to the United States, opened the roundtable with a virtual address urging governments to treat women's physical and mental health as interconnected rather than episodic. She argued that no nation can rely on half its population to drive economic growth while leaving their healthcare needs to chance.

Apollo Athenaa Treats 30,000 Women, Marks 1,000+ Cancer Surgeries in Year One

New Delhi – September 20, 2026 -- Apollo Athenaa Women's Cancer Centre has treated more than 30,000 women from over 110 cities and performed 1,000-plus cancer surgeries in its first year of operation, marking its anniversary as Asia's first dedicated cancer centre for women.

Centre completes 4,000+ chemotherapy cycles and 100+ reconstruction procedures in year one

Apollo Athenaa's clinical volumes in its debut year include over 4,000 chemotherapy cycles, more than 100 plastic and breast reconstruction procedures, and 120-plus VABB (vacuum-assisted breast biopsy) procedures. The centre built an integrated care model spanning breast and gynaecological oncology, reconstruction, medical and precision oncology, diagnostics and rehabilitation.

EMD Serono Acquires PostEra's Oral Fertility Drug Programs

Boston – September 15, 2026 -- EMD Serono, Inc., the U.S. and Canada healthcare business of Merck KGaA, Darmstadt, Germany, has acquired two preclinical fertility drug programs from PostEra, a biotechnology company that uses artificial intelligence for small-molecule drug discovery.

EMD Serono takes over two AI-derived fertility programs from PostEra

The deal covers a class of follicle-stimulating hormone receptor (FSHR) agonists for ovarian stimulation in IVF and a separate class of luteinizing hormone/chorionic gonadotropin receptor (LHCGR) agonists targeting male infertility and ovulation triggering in IVF. Both programs were developed over the past two years using PostEra's Proton AI platform and remain in preclinical development, with safety and efficacy in humans not yet established.